This Blockbuster Drug's Latest News Could Be Another Home Run for AbbVie

This Blockbuster Drug's Latest News Could Be Another Home Run for AbbVie

Source: 
Motley Fool
snippet: 
  • Skyrizi’s recently announced phase 3 clinical trial results to treat ulcerative colitis demonstrate that it is effective.
  • An ulcerative colitis indication in the U.S. could be a blockbuster all on its own.
  • AbbVie is attractively valued at the current share price.